🔥MetabolicLongevityUnder FDA Review

MOTS-c

Mitochondrial Open Reading Frame of the 12S rRNA-c

In simple terms

MOTS-c is a peptide people usually talk about for Obesity and Type 2 diabetes / insulin resistance. It is still in the FDA review process, so people are watching both the research and the access question closely.

Why does this matter?

MOTS-c matters because a lot of people hear about it online without a clear sense of what it may actually help with. This page gives you the plain-English version first, then shows where the research is strongest, what is still uncertain, and where the peptide stands in the FDA review process.

Molecular weight

2,174.64 g/mol

Molecular formula

C₁₀₁H₁₅₂N₂₈O₂₂S₂

Amino acid count

16

Review date

July 23-24, 2026

Sequence / structure

MRWQEMGYIFYPRKLR (16 amino acids)

Other names

MOTS-c, Mitochondrial ORF of the 12S rRNA type-c, Mitochondrial-derived peptide MOTS-c, Exercise mimetic peptide

Status

Under FDA review for obesity and osteoporosis

Research summary

MOTS-c is a mitochondrial peptide that acts a lot like an exercise signal inside the body. It is best known for helping cells handle energy better, improving insulin sensitivity, and supporting fat burning in ways that make it especially interesting for metabolism and weight-management conversations. That “exercise mimetic” angle is what makes it stand out, because it seems to push some of the same pathways people want from training and metabolic conditioning.

How it works

The quick version before the deep dive

  • People usually talk about MOTS-c for Obesity and Type 2 diabetes / insulin resistance.
  • Type 2 diabetes / insulin resistance.
  • Directly activates AMP-activated protein kinase, the master metabolic sensor.
  • Inhibits the folate cycle, leading to AICAR accumulation → AMPK activation.
Deep Dive: Mechanism of Action +
1

AMPK Activation — Directly activates AMP-activated protein kinase, the master metabolic sensor

2

Folate-Methionine Cycle Disruption — Inhibits the folate cycle, leading to AICAR accumulation → AMPK activation

3

Nuclear Translocation — Under stress, MOTS-c moves from cytoplasm to nucleus and regulates adaptive gene expression (ARE/ERE genes)

4

Insulin Sensitization — Improves glucose uptake in skeletal muscle independent of insulin

5

Fat Oxidation — Enhances fatty acid oxidation and reduces fat accumulation

6

Exercise Mimetic — Activates same pathways as physical exercise (AMPK, PGC-1α)

7

Mitochondrial Biogenesis — Promotes new mitochondria formation

8

Osteoblast Activation — Stimulates bone-forming cells, relevant to osteoporosis prevention

9

Retrograde Signaling — Represents mitochondria-to-nucleus communication (novel biological paradigm)

Clinical applications

Where people usually see it discussed

Metabolic +
  • Obesity (FDA review indication)
  • Type 2 diabetes / insulin resistance
  • Metabolic syndrome
  • Non-alcoholic fatty liver disease (NAFLD)
Musculoskeletal +
  • Osteoporosis (FDA review indication)
  • Sarcopenia (age-related muscle loss)
  • Exercise performance enhancement
  • Physical rehabilitation
Aging/Longevity +
  • Healthspan extension
  • Age-related metabolic decline
  • Mitochondrial dysfunction
  • Cellular senescence
Cardiovascular +
  • Endothelial function
  • Atherosclerosis prevention (preclinical)
Clinical trials

Formal evidence and study snapshots

Deep Dive: Clinical Trials +

Lee et al. 2015 (Cell Metab.)

Preclinical

Obesity/diabetes

Prevented diet-induced obesity, improved insulin sensitivity in mice

Lee et al. 2019

Preclinical

Exercise/aging

Improved physical performance in aged mice to youthful levels

Kim et al. 2018

Preclinical

Stress response

Nuclear translocation under metabolic stress

Ming et al. 2016

Preclinical

Bone

Prevented ovariectomy-induced osteoporosis

Human observational

Clinical

Biomarker

Circulating MOTS-c decreases with age, increases with exercise

Safety profile

What the current safety discussion looks like

  • Endogenous peptide — Naturally produced by human mitochondria
  • Circulating in healthy humans — Present in blood at detectable levels; decreases with age
  • No reported toxicity in animal models at therapeutic doses
  • Theoretical concerns:
  • Unknown long-term effects of exogenous AMPK activation
  • Potential interaction with metformin (both activate AMPK)
  • Cancer considerations unclear (AMPK activation generally considered tumor-suppressive)
  • No hepatotoxicity or nephrotoxicity reported
  • Well-tolerated in all published animal studies
Regulatory status

How the status timeline currently reads

Pre-2023

Category 1 — eligible for 503A compounding

September 2023

Moved to Category 2

April 2026

FDA announces PCAC review

July 23-24, 2026

Advisory committee review for obesity and osteoporosis

Dosing information

How dosing is usually described

Subcutaneous Injection

Metabolic support: 5-10 mg/week (divided into daily or EOD doses) Common protocol: 5 mg injected SubQ 3-5x per week Cycle length: 4-8 weeks

Timing

Often administered in the morning to align with circadian metabolic rhythms Some protocols time with exercise for synergistic AMPK activation

Reconstitution

Lyophilized powder reconstituted with bacteriostatic water Stored refrigerated after reconstitution

Research protocols only. Not medical advice.

Key papers

The citations behind the page

Deep Dive: Key Research Papers +
  1. 1

    Lee C, et al.*. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism 2015.

  2. 2

    Kim SJ, et al.*. "The mitochondrial-derived peptide MOTS-c translocates to the nucleus under metabolic stress." Cell Reports 2018.

  3. 3

    Reynolds JC, et al.*. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications 2021.

  4. 4

    Ming W, et al.*. "Mitochondria-derived peptide MOTS-c attenuates ovariectomy-induced bone loss." Biochemical and Biophysical Research Communications 2016.

  5. 5

    Lee C, et al.*. "MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism." Free Radical Biology and Medicine 2019.

  6. 6

    Zhai D, et al.*. "MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA." Molecular Immunology 2017.

  7. 7

    Kim SJ, et al.*. "Mitochondrial peptides modulate mitochondrial function during cellular senescence." Aging 2018.

FAQ

Common questions about MOTS-c

What is MOTS-c? +

MOTS-c is Mitochondrial Open Reading Frame of the 12S rRNA-c, one of the peptides currently under review in connection with obesity and osteoporosis.

What is MOTS-c being reviewed for? +

The current advisory review focuses on obesity and osteoporosis, with a listed review date of July 23-24, 2026.

Which category does MOTS-c belong to? +

MOTS-c is grouped in this library under Metabolic and Longevity.

How many amino acids are in MOTS-c? +

MOTS-c is presented here as a 16-amino-acid peptide or peptide analog based on the source research and naming conventions.

What is the sequence or structure note for MOTS-c? +

MRWQEMGYIFYPRKLR (16 amino acids).

What research applications are most associated with MOTS-c? +

Obesity, Type 2 diabetes / insulin resistance, Metabolic syndrome, and Non-alcoholic fatty liver disease

How is MOTS-c described as working in the current research? +

Directly activates AMP-activated protein kinase, the master metabolic sensor. Inhibits the folate cycle, leading to AICAR accumulation → AMPK activation.

How is MOTS-c usually discussed in protocols or treatment plans? +

MOTS-c is most often described with under-the-skin injection and timing protocols in the source material.

What does the safety discussion say about MOTS-c? +

Endogenous peptide — Naturally produced by human mitochondria Circulating in healthy humans — Present in blood at detectable levels; decreases with age

Stay informed

Get notified when MOTS-c becomes available

Join the waitlist for peptide-specific updates, regulatory milestones, and access news connected to the GobyMeds care pathway.

GobyPeptides

GobyPeptides.com is an educational resource covering available-now treatments and research-tracked peptides. Backed by GobyMeds, a physician-led telehealth company.

Currently available treatments at GobyMeds →

Stay Updated

Get notified when review milestones move or new treatments launch.

© 2026 GobyPeptides. Content is not medical advice. Consult a healthcare provider.